Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

Patients with myelofibrosis (MF) experience an array of symptoms that impair health-related quality of life (HRQoL). Fedratinib, an oral, selective Janus-kinase 2 (JAK2) inhibitor, was investigated in the randomized, placebo-controlled, phase III JAKARTA study in adult patients with intermediate- or...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesa, Ruben A., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Rose, Shelonitda, Abraham, Pranav, Lord-Bessen, Jennifer, Tang, Derek, Guo, Shien, Ye, Xiaomei, Harrison, Claire N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096463/
https://www.ncbi.nlm.nih.gov/pubmed/33969273
http://dx.doi.org/10.1097/HS9.0000000000000553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096463/
https://www.ncbi.nlm.nih.gov/pubmed/33969273
http://dx.doi.org/10.1097/HS9.0000000000000553

Ejemplares similares